Skip to main content
SpringerLink
Log in

Autoantibodies in Raynaud’s Phenomenon

  • Chapter
  • First Online:
Raynaud’s Phenomenon

Abstract

The identification of autoantibodies associated with Raynaud’s phenomenon (RP) provides intriguing insight into the relationship between autoimmunity and vascular function in health and disease. Autoantibodies can help identify patients with RP at risk of developing an associated autoimmune rheumatic disease in which RP can be the presenting symptom, e.g., systemic sclerosis. Recent work has identified autoantibodies that may contribute to the pathogenesis of vascular dysfunction in diseases associated with RP. In this chapter, we shall discuss the various methods of autoantibody detection, their diagnostic and prognostic importance, and the potential contribution of autoantibodies in the pathogenesis of vascular dysfunction in RP.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACA:

Anti-centromere antibodies

aCL:

Anticardiolipin antibodies

ANA:

Antinuclear antibody

ANCA:

Anti-neutrophil cytoplasmic antibody

Anti-RNA Pol:

Anti-RNA polymerase

Anti-Scl 70:

Anti-scleroderma 70 antibody

APLA:

Antiphospholipid antibodies

APLS:

Antiphospholipid syndrome

ARD:

Autoimmune rheumatic disease

CENP-B:

Centromere protein B

CTD:

Connective tissue disease

DM:

Dermatomyositis

dsDNA:

Anti-double-stranded DNA antibody

DU:

Digital ulceration

ELISA:

Enzyme-linked immunosorbant assay

ENA:

Extractable nuclear antigens

FITC:

Fluorescein isothiocyanate

HEp2:

Human epithelial 2 cell

IIF:

Indirect immunofluorescence

IP:

Immunoprecipitation

Jo-1:

Histadyl tRNA synthetase autoantibodies

LA:

Lupus anticoagulant

LR-:

Negative likelihood ratio

LR+:

Positive likelihood ratio

MCTD:

Mixed connective tissue disease

Mi-2:

Mi-2 antibody

PAH:

Pulmonary arterial hypertension

PM:

Polymyositis

PSS:

Primary Sjogren’s syndrome

RA:

Rheumatoid arthritis

RF:

Rheumatoid factor

RP:

Raynaud’s phenomenon

SLE:

Systemic lupus erythematosus

Sm:

Smith

SRP:

Signal recognition particle

SSc:

Systemic sclerosis

Th:

Ribonuclease mitochondrial RNA processing

To:

Ribonuclease P complexes

U1RNP:

U1 ribonucleoprotein

U3RNP:

U3 ribonucleoprotein

β2-GP-I:

Anti-β2 glycoprotein-I

References

  1. Hepburn AL. The LE, cell. Rheumatology. 2001;40(7):826–7.

    Article  PubMed  CAS  Google Scholar 

  2. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol. 2009;19(3):219–28.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Qin X, Tao X, Chen ZJ, Jiang JQ, Xu MH, Li RL, et al. [Comparison of indirect immunofluorescence assay and ELISA for detecting antinuclear antibodies and anti-double-stranded DNA antibodies]. Nan fang yi ke da xue xue bao. 2009;29(3):472–5.

    PubMed  CAS  Google Scholar 

  4. Dunphy J. BIRD diagnostics user manual [25.07.2012]. Available from: http://www.birdbath.org.uk/pdfs/User-Manual_Edition-42.pdf.

  5. Robinson JP, Sturgis J, Kumar GL. Immunofluorescence. In: Kumar GL, Rudbeck L, editors. Immunohistochemical staining methods. 5th Ed. Carpinteria, CA: Dato 2009 1–6.

    Google Scholar 

  6. Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434–44.

    Article  PubMed  Google Scholar 

  7. Self SE. Autoantibody testing for autoimmune disease. Clin Chest Med. 2010;31(3):415–22.

    Article  PubMed  Google Scholar 

  8. Buchanan RR, Riglar AG. The titre of anti-centromere antibodies: its relationship to Raynaud’s phenomenon and vascular occlusion. Br J Rheumatol. 1989;28(3):221–6.

    Article  PubMed  CAS  Google Scholar 

  9. Crowther JR. The ELISA guidebook. 2nd ed. New York, NY: Springer; 2009.

    Book  Google Scholar 

  10. Avaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clin Vaccine Immunol. 2007;14(5):505–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Bonilla E, Francis L, Allam F, Ogrinc M, Neupane H, Phillips PE, et al. Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol. 2007;124(1):18–21.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Eissfeller P, Sticherling M, Scholz D, Hennig K, Luttich T, Motz M, et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann N Y Acad Sci. 2005;1050:327–39.

    Article  PubMed  CAS  Google Scholar 

  13. Nifli AP, Notas G, Mamoulaki M, Niniraki M, Ampartzaki V, Theodoropoulos PA, et al. Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. J Immunol Methods. 2006;311(1–2):189–97.

    Article  PubMed  CAS  Google Scholar 

  14. Gallagher S, Winston SE, Fuller SA, Hurrell JG. Immunoblotting and immunodetection. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Shwartz J, Yamada KM, editors. Current protocols in cell biology. 2011. Chapter 6:Unit6 2.

    Google Scholar 

  15. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53(6):424–32.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis. 1993;52(12):857–61.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124(1):71–81.

    PubMed  CAS  Google Scholar 

  18. Isenberg DA, Black C. ABC of rheumatology. Raynaud’s phenomenon, scleroderma, and overlap syndromes. BMJ. 1995;310(6982):795–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Saigal R, Kansal A, Mittal M, Singh Y, Ram H. Raynaud’s phenomenon. J Assoc Physicians India. 2010;58:309–13.

    PubMed  Google Scholar 

  20. Ziegler S, Brunner M, Eigenbauer E, Minar E. Long-term outcome of primary Raynaud’s phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol. 2003;32(6):343–7.

    Article  PubMed  CAS  Google Scholar 

  21. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud’s phenomenon: a long-term prospective study. J Rheumatol. 1995;22(12):2226–32.

    PubMed  CAS  Google Scholar 

  22. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158(6):595–600.

    Article  PubMed  CAS  Google Scholar 

  23. Garza-Rodriguez V, Villarreal-Alarcon MA, Ocampo-Candiani J. [Scleroderma: an update on the pathogenesis and treatment]. Rev Med Inst Mex Seguro Soc. 2013;51(1):50–7.

    PubMed  Google Scholar 

  24. Beck JS, Anderson JR, Gray KG, Rowell NR. Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet. 1963;2(7319):1188–90.

    PubMed  CAS  Google Scholar 

  25. Beck JS. Auto-antibodies to cell nuclei. Scott Med J. 1963;8:373–88.

    PubMed  CAS  Google Scholar 

  26. Rothfield NF, Rodnan GP. Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1968;11(5):607–17.

    Article  PubMed  CAS  Google Scholar 

  27. Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31(2):196–203.

    Article  PubMed  CAS  Google Scholar 

  28. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35–42.

    Article  PubMed  CAS  Google Scholar 

  29. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger Jr TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007;34(1):104–9.

    PubMed  Google Scholar 

  30. Betteridge Z, Woodhead F, Bunn C, Denton C, Abraham D, Desai S, et al. Anti-EIF2 is associated with interstitial lung disease in patients with systemic sclerosis. Rheumatology. 2012;51 Suppl 3:2.

    Google Scholar 

  31. Admou B, Essaadouni L, Amal S, Arji N, Chabaa L, El Aouad R. [Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach]. Ann Biol Clin. 2009;67(3):273–81.

    CAS  Google Scholar 

  32. Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger Jr TA, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 2009;61(7):958–65.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.

    Article  PubMed  Google Scholar 

  34. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–81.

    Article  PubMed  CAS  Google Scholar 

  35. LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573–6.

    PubMed  CAS  Google Scholar 

  36. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L, et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2013.

    Google Scholar 

  37. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. A prospective study. Arthritis Rheum. 1991;34(1):68–77.

    Article  PubMed  CAS  Google Scholar 

  38. Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C, et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology. 2010;49(4):797–805.

    Article  PubMed  CAS  Google Scholar 

  39. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902–12.

    Article  PubMed  Google Scholar 

  40. Denton CP, Black CM. Scleroderma–clinical and pathological advances. Best Pract Res Clin Rheumatol. 2004;18(3):271–90.

    Article  PubMed  CAS  Google Scholar 

  41. Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 2012;71(5):718–21.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol. 2007;19(6):580–91.

    Article  PubMed  Google Scholar 

  43. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355–60.

    Article  PubMed  Google Scholar 

  44. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340–54.

    Article  PubMed  CAS  Google Scholar 

  45. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger Jr TA. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 2003;48(1):203–9.

    Article  PubMed  Google Scholar 

  46. Sunderkotter C, Herrgott I, Bruckner C, Moinzadeh P, Pfeiffer C, Gerss J, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol. 2009; 160(4):835–43.

    Article  PubMed  CAS  Google Scholar 

  47. Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol. 2012;43(3):249–55.

    Article  PubMed  CAS  Google Scholar 

  48. Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol. 2008;158(1):141–4.

    PubMed  CAS  Google Scholar 

  49. Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol. 2005;23(2):199–204.

    PubMed  CAS  Google Scholar 

  50. Yaqub A, Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2013;15(1):302.

    Article  PubMed  Google Scholar 

  51. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15(1):102–9.

    Article  PubMed  Google Scholar 

  52. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516–22.

    Article  PubMed  Google Scholar 

  53. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26(1):61–72.

    Article  PubMed  CAS  Google Scholar 

  54. Shi YH, Li R, Chen S, Su Y, Jia Y. [Analysis of clinical features and the outcome in 91 cases of mixed connective tissue diseases]. Beijing da xue xue bao Yi xue ban. 2012;44(2):270–4.

    Google Scholar 

  55. Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity. 2006;39(3):243–7.

    Article  PubMed  CAS  Google Scholar 

  56. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33(9):1361–70.

    Article  PubMed  CAS  Google Scholar 

  57. Dimant J, Ginzler E, Schlesinger M, Sterba G, Diamond H, Kaplan D, et al. The clinical significance of Raynaud’s phenomenon in systemic lupus erythematosus. Arthritis Rheum. 1979;22(8):815–9.

    Article  PubMed  CAS  Google Scholar 

  58. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10(5):541–7.

    PubMed  CAS  Google Scholar 

  59. Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol. 2000;27(6):1403–7.

    PubMed  CAS  Google Scholar 

  60. Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int. 2011;31(2):183–9.

    Article  PubMed  CAS  Google Scholar 

  61. Caccavo D, Del Porto F, Garzia P, Mitterhofer AP, Galluzzo S, Rigon A, et al. Raynaud’s phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? Ann Rheum Dis. 2003;62(10):1003–5.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  62. Garcia-Carrasco M, Siso A, Ramos-Casals M, Rosas J, de la Red G, Gil V, et al. Raynaud’s phenomenon in primary Sjogren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002;29(4):726–30.

    PubMed  Google Scholar 

  63. Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM. Anticentromere antibody positive Sjogren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010;12(2):R47.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, Gil V, Delgado G, et al. Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006;35(5):312–21.

    Article  PubMed  CAS  Google Scholar 

  65. Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjogren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007; 34(11):2253–8.

    PubMed  CAS  Google Scholar 

  66. Katano K, Kawano M, Koni I, Sugai S, Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjogren’s syndrome. J Rheumatol. 2001;28(10):2238–44.

    PubMed  CAS  Google Scholar 

  67. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol. 2005; 32(8):1488–94.

    PubMed  Google Scholar 

  68. Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, et al. Sjogren’s syndrome with anticentromere antibodies. Rev Rhum. 1997;64(12):785–8.

    CAS  Google Scholar 

  69. Font J, Ramos-Casals M, Cervera R, Bosch X, Mirapeix E, Garcia-Carrasco M, et al. Antineutrophil cytoplasmic antibodies in primary Sjogren’s syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37(12):1287–91.

    Article  PubMed  CAS  Google Scholar 

  70. Ohishi K, Kanoh M, Shinomiya H, Hitsumoto Y, Utsumi S. Complement activation by cross-linked B cell-membrane IgM. J Immunol. 1995;154(7):3173–9.

    PubMed  CAS  Google Scholar 

  71. Frisoni L, McPhie L, Colonna L, Sriram U, Monestier M, Gallucci S, et al. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity? J Immunol. 2005;175(4):2692–701.

    Article  PubMed  CAS  Google Scholar 

  72. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44(5):587–96.

    Article  PubMed  CAS  Google Scholar 

  73. Salozhin KV, Shcherbakov AB, Nasonov EL, Kolesova NV, Romanov Iu A, Guseva NG. [Antiendothelial antibodies in systemic scleroderma and Raynaud’s disease]. Ter Arkh. 1995;67(5):54–7.

    PubMed  CAS  Google Scholar 

  74. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25(3):462–6.

    PubMed  CAS  Google Scholar 

  75. Dib H, Tamby MC, Bussone G, Regent A, Berezne A, Lafine C, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405–14.

    Article  PubMed  CAS  Google Scholar 

  76. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996; 98(3):785–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  77. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud’s phenomenon. Ann Intern Med. 1981;94(4 pt 1):482–4.

    Article  PubMed  CAS  Google Scholar 

  78. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 1991;34(8): 978–83.

    Article  PubMed  CAS  Google Scholar 

  79. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol. 1994;101(1):109–13.

    PubMed  CAS  Google Scholar 

  80. Gruschwitz MS, Hornstein OP, von Den DP. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 1995;38(2):184–9.

    Article  PubMed  CAS  Google Scholar 

  81. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology. 1993;61(5–6):239–46.

    Article  PubMed  CAS  Google Scholar 

  82. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the “uninvolved skin”. Arthritis Rheum. 1991;34(12):1495–501.

    Article  PubMed  CAS  Google Scholar 

  83. Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996;97(1):111–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  84. Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010; 69(2):319–24.

    Article  PubMed  CAS  Google Scholar 

  85. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43(11):2550–62.

    Article  PubMed  CAS  Google Scholar 

  86. Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2003;32(5):285–95.

    Article  PubMed  CAS  Google Scholar 

  87. Szodoray P, Hajas A, Kardos L, Dezso B, Soos G, Zold E, et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21(13):1412–22.

    Article  PubMed  CAS  Google Scholar 

  88. Bodolay E, Csipo I, Gal I, Sipka S, Gyimesi E, Szekanecz Z, et al. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol. 2004;22(4):409–15.

    PubMed  CAS  Google Scholar 

  89. Lage LV, de Carvalho JF, Caleiro MT, Yoshinari NH, da Mota LM, Khamashta MA, et al. Fluctuation of anti-endothelial cell antibody titers in " mixed connective tissue disease. Isr Med Assoc J. 2012;14(2):84–7.

    PubMed  Google Scholar 

  90. Hebbar M, Lassalle P, Delneste Y, Hatron PY, Devulder B, Tonnel AB, et al. Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjogren’s syndrome. Ann Rheum Dis. 1997;56(4):230–4.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  91. Liu MF, Lei HY. Anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Taiwan yi zhi. 1991;90(3):221–4.

    PubMed  CAS  Google Scholar 

  92. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354(25):2667–76.

    Article  PubMed  CAS  Google Scholar 

  93. Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum. 2009;60(4): 1145–51.

    Article  PubMed  CAS  Google Scholar 

  94. Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 2009;60(4):1137–44.

    Article  PubMed  CAS  Google Scholar 

  95. Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S204–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

 Special thanks to Bath Institute for Rheumatic Diseases diagnostics laboratory for their support and provision of illustrative photos of immunofluorescence and immunoprecipitation.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA1 1RL, UK

    Victoria Flower M.B.B.S., B.Sc. Hons., M.R.C.P. (Specialty Rheumatology Registrar)

  2. Division of Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA1 1RL, UK

    John D. Pauling B.Med.Sci., M.R.C.P.(Rheumatology), Ph.D. (Consultant Rheumatologist, Visiting Senior Lecturer)

  3. Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK

    John D. Pauling B.Med.Sci., M.R.C.P.(Rheumatology), Ph.D. (Consultant Rheumatologist, Visiting Senior Lecturer)

  4. Division of Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA1 1RL, UK

    Neil McHugh BM.B.Ch.B., M.D. (thesis), F.R.A.C.P., F.R.C.P., F.R.C.Path. (Consultant Rhematologist, Professor of Pharmacoepidemiology)

  5. Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK

    Neil McHugh BM.B.Ch.B., M.D. (thesis), F.R.A.C.P., F.R.C.P., F.R.C.Path. (Consultant Rhematologist, Professor of Pharmacoepidemiology)

Authors
  1. Victoria Flower M.B.B.S., B.Sc. Hons., M.R.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Pauling B.Med.Sci., M.R.C.P.(Rheumatology), Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil McHugh BM.B.Ch.B., M.D. (thesis), F.R.A.C.P., F.R.C.P., F.R.C.Path.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil McHugh BM.B.Ch.B., M.D. (thesis), F.R.A.C.P., F.R.C.P., F.R.C.Path. .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

    Fredrick M. Wigley

  2. Department of Rheumatology, The University of Manchester, Manchester, United Kingdom

    Ariane L. Herrick

  3. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medic, Baltimore, Maryland, USA

    Nicholas A. Flavahan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Flower, V., Pauling, J.D., McHugh, N. (2015). Autoantibodies in Raynaud’s Phenomenon. In: Wigley, F., Herrick, A., Flavahan, N. (eds) Raynaud’s Phenomenon. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1526-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1526-2_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1525-5

  • Online ISBN: 978-1-4939-1526-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation